Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
Bestvina C.M. Whisenant J.G. Torri V. Cortellini A. Wakelee H. Peters S. Roca E. De Toma A. Hirsch F.R. Mamdani H. Halmos B. Arrieta O. Metivier A.-C. Fidler M.J. Rogado J. Presley C.J. Mascaux C. Genova C. Blaquier J.B. Addeo A. Finocchiaro G. Khan H. Mazieres J. Morgillo F. Bar J. Aujayeb A. Mountzios G. Scotti V. Grosso F. Geraedts E. Zhumagaliyeva A.N. Horn L. Garassino M.C. Baena J.
August 2022Elsevier Inc.
JTO Clinical and Research Reports
2022#3Issue 8
Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
Cancer , COVID-19 , NSCLC , Registry , TERAVOLT , Thoracic
Text of the article Перейти на текст статьи
Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, Illinois
Vanderbilt University Medical Center, Nashville, Tennessee
Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
Department of Surgery and Cancer, Imperial College London, London, United Kingdom
Stanford Cancer Institute, Stanford University, Stanford, California
Lausanne University Hospital, Lausanne University, Lausanne, Switzerland
Thoracic Oncology—Lung Unit, Ospedale Pederzoli, G, Verona, Italy
Thoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy
Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine Mount Sinai, New York, New York
Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States
Division of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, United States
Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico
Department of Pneumology, Hopital Foch, Suresnes, France
Department of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, Illinois
Seccion de Oncologia Medica, Hospital Universitario Infanta Leonor, Madrid, Spain
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States
Service De Pneumologie, Hopitaux Universitaires De Strasbourg, Strasbourg, France
Laboratory Streinth (Stress REsponse and INnovative THerapy against Cancer), Inserm UMR_S 1113, IRFAC, ITI InnoVec, Universite De Strasbourg, Strasbourg, France
UOC Clinica di Oncologia Medica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genoa, Italy
Dipartimento di Medicina Interna e Specialita Mediche (DIMI), Universita degli Studi di Genova, Genoa, Italy
Thoracic Oncology Section, Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina
University Hospital of Geneva, Geneva, Switzerland
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy
The Warren Alpert Medical School of Brown University, Providence, Rhode Island
Toulouse University Hospital, Université Paul Sabatier, Toulouse, France
Department of Precision Medicine, Medical Oncology and Haematology, Universita degli studi della Campania “L. Vanvitelli,”, Naples, Italy
Institute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel
Respiratory Department, Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
Fourth Department of Medical Oncology and Clinical Trials Unit Henry Dunant Hospital Center, Athens, Greece
Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, Italy
Mesothelioma and Rare Cancer Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Groene Hart Ziekenhuis, Gouda, Netherlands
Semey Medical University, Center for Nuclear Medicine and Oncology of Semey, Semey, Kazakhstan
Hospital Universitario 12 de Octubre, Madrid, Spain
Department of Medicine
Vanderbilt University Medical Center
Oncology Department
Department of Surgery and Cancer
Stanford Cancer Institute
Lausanne University Hospital
Thoracic Oncology—Lung Unit
Thoracic Oncology Unit
Center for Thoracic Oncology
Department of Oncology
Division of Oncology
Thoracic Oncology Unit
Department of Pneumology
Department of Hematology
Seccion de Oncologia Medica
Division of Medical Oncology
Service De Pneumologie
Laboratory Streinth (Stress REsponse and INnovative THerapy against Cancer)
UOC Clinica di Oncologia Medica
Dipartimento di Medicina Interna e Specialita Mediche (DIMI)
Thoracic Oncology Section
University Hospital of Geneva
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital
The Warren Alpert Medical School of Brown University
Toulouse University Hospital
Department of Precision Medicine
Institute of Oncology
Respiratory Department
Fourth Department of Medical Oncology and Clinical Trials Unit Henry Dunant Hospital Center
Department of Oncology
Mesothelioma and Rare Cancer Unit
Groene Hart Ziekenhuis
Semey Medical University
Hospital Universitario 12 de Octubre
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026